Bristol-Myers Squibb Co. Community Page | What other sites are saying about Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

(NY: BMY)

46.85 USD +0.41 (+0.88%)

Official Closing Price / Updated: 6:40 PM EDT, Jun 18, 2013 / Add to My Watchlist

(BMY) Community Analysis from

Related Wikinvest articles

June 18, 2013

(BMY) Bristol-Myers Squibb Company Earns Good News From FDA

(Stock Blog Hub, 5/18/13)

Bristol-Myers Squibb Company (BMY) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma...(read more)

(MRK) Merck & Company Joins Forces With Bristol-Myers Squibb on Hepatitis C Virus Candidates

(Stock Blog Hub, 5/14/13)

Merck & Co. Inc. (MRK) recently joined forces with Bristol-Myers Squibb (BMY) to conduct a phase II study with their hepatitis C virus...(read more)

Is it Time to Buy More Gold?

(Investment U, 2/8/13)

Will This Drug Be The Next Hit? Is it Time to Load Up on Some Gold? The "Slap in the Face" Award: Shanghai Edition...

View all posts about Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY) Company Overview

This article is about Bristol-Myers Squibb. For the article on the company with ticker BMS, see Bemis Company (BMS).

Bristol-Myers Squibb (NYSE: BMY) is one of the world's largest pharmaceutical companies by total sales. Bristol-Myers Squibb offers treatments for cardiovascular disease, HIV/AIDS, hepatitis, cancer, and rheumatoid arthritis. Cancer treatments in particular represent a major portion of the company's long-term growth potential and have historically been a strong suit of Bristol-Myers Squibb. The company's top three blockbuster drugs (annual sales >$1 billion) are blood thinner Plavix, Abilify for schizophrenia, and Reyataz for HIV. In FY 2010, BMY generated revenues of $19.5B and net earnings of $3.1B.^[1]

(Read more at Wikinvest

)

What's in this BMY analysis on Wikinvest...